Patented and specialty medicines, novel molecules (NCEs/NBEs) and the R&D and out-licensing that create them.
Sun Pharmaceutical IndustriesOwner · HighListed
Glenmark PharmaceuticalsOwner · HighListed
WockhardtOwner · HighListed
Zydus LifesciencesOwner · MediumListed
LupinOwner · LowListed
SPARC (Sun Pharma Advanced Research Company)Emerging entrant · HighListed
Wockhardt (WOCKPHARMA)
Antibiotic discovery company - first Indian-discovered NCE antibiotic approved by the US FDA (Zaynich, 2026) - plus generics in India, UK and emerging markets
Price
₹1,901
snapshot 30 Oct 2026
Strengths
Zaynich (cefepime-zidebactam) approved by USFDA (mid-2026) for drug-resistant infections; EMA filing accepted for accelerated assessment
Novel antibiotic pipeline (Miqnaf/nafithromycin approved in India)
FY26 was the first profitable year after a long loss run
Risks
Commercial success of a new antibiotic in the US is notoriously hard (hospital uptake, stewardship)
History of USFDA import alerts and leverage
Valuation now prices in a successful Zaynich launch
Note: Loss-making through FY25; FY26 is the first profitable year in the series
Market cap, ratios, CAGR and revenue: company table snapshot as of 30 Oct 2026 (the same figures on every page). Price: snapshot as of 30 Oct 2026. Not investment advice.
Where it fits
Discovers, in-licenses or acquires patented and differentiated medicines and sells them at innovator prices, mainly in the US and Europe through specialist sales teams - the step up from copying molecules to owning them.
Why it matters
Specialty is the only layer that escapes generic price erosion. Sun Pharma's innovative medicines (Ilumya, Cequa, Winlevi, Leqselvi, Unloxcyt) are now over a fifth of its sales; Glenmark's US$700m upfront from AbbVie for ISB 2001 and Wockhardt's FDA-approved antibiotic Zaynich show Indian R&D producing globally valued assets. Successes here re-rate a whole company.
Where the value pool sits
Innovator-style gross margins (80%+) and long patent lives, but heavy front-loaded spend: launch costs, specialist field forces and clinical trials. Value is binary - a Phase 3 failure or a slow launch can wipe out years of R&D (typically 6-9% of sales for Indian leaders; far more for pure R&D plays).
Key drivers
Out-licensing deals with global pharma (upfronts plus milestones and royalties)
Specialty acquisitions (Sun-Organon, US$11.75bn EV, expected to close early 2027)
Biopharma SHAKTI (₹10,000 Cr over five years, Budget 2026-27) and PRIP research incentives
Rising US demand for new antibiotics, dermatology and oncology assets
Potential bottlenecks
Small R&D budgets versus global innovators (Indian leaders spend ~US$100-400m a year)
Few Indian companies have US/EU specialty sales infrastructure
Slow Indian clinical-trial approvals (CDSCO) push trials abroad
Investor metrics to watch
Specialty / innovative share of revenue
R&D spend as % of sales and pipeline stage mix
Launch trajectories of new specialty brands (scripts, net sales)
Milestone and royalty income from out-licensed assets